The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...
6 天
The Brighterside of News on MSNRevolutionary new drug is a major breakthrough in diabetes careDiabetes affects millions worldwide, often triggering complications such as insulin resistance and fatty liver disease. To ...
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Alongside this research, other studies have shown that lifestyle choices can also help manage diabetes. Eating more whole ...
Biomedical engineer Joshua Doloff uses federal funding to pioneer immunotherapies that could free diabetes patients from ...
5 天on MSN
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
1 天
News Medical on MSNExpanding access to anti-obesity medications delivers 13% return on investment for societyBroad access to new obesity drugs leads to longer, healthier lives, delivering a substantial societal return on investment, ...
The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...
ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.
For instance, some type 2 diabetes medications can cause hypoglycemia when taken together, so you and your doctor should also consider your current treatment if you’re adding a new medication to ...
In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果